Company intelligence / Profile preview
Dilafor AB
Swedendilafor.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Dilafor AB develops tafoxiparin, a proprietary heparan sulfate mimetic designed to improve cervical ripening and facilitate the onset of labor. Clinical studies have shown that tafoxiparin can significantly increase the rate of spontaneous onset of labor or achievement of a ripe cervix, with demonstrated safety in over 650 pregnant women. The drug aims to reduce maternal/fetal complications associated with induced or protracted labor. Recent extension studies have yielded positive results supporting continued development.
- Therapeutic areas
- Women's Health
- Modalities
- Small molecules (heparan sulfate mimetic)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lee’s Pharmaceutical Holdings Limited/Lee’s Healthcare Industry Fund L.P.: License agreement for development/commercialization in China, Hong Kong, Macau, Taiwan.Opocrin SpA (API expertise partner/investor)
Beyond the preview
Go deeper on Dilafor AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dilafor AB.